Literature DB >> 10761449

Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients.

H Wu1, M A Wasik, G Przybylski, J Finan, B Haynes, H Moore, D G Leonard, K T Montone, A Naji, P C Nowell, M Kamoun, J E Tomaszewski, K E Salhany.   

Abstract

We report 2 cases of renal transplant recipients in whom hepatosplenic gamma-delta T-cell lymphoma (gamma-delta HSTCL) developed 5 and 10 years after transplantation. Both patients had marked hepatosplenomegaly, B symptoms (weight loss, fever, and night sweats), and abnormal peripheral blood findings, including anemia in both, thrombocytopenia and leukoerythroblastic changes in 1, and leukocytosis in the other. Markedly atypical lymphoid infiltrate of intermediate to large cells was observed in the spleen, liver, and bone marrow. The malignant cells showed typical immunophenotype of gamma-delta T cells (CD2+, CD3+, CD4-, CD8-, CD7+, gamma-delta T-cell receptor-positive, and alpha-beta T-cell receptor-negative) with clonal T-cell receptor gene rearrangement and were of the V-delta-1 subset. In addition, the cells contained a cytolytic granule-associated protein, TIA-1, and Fas ligand, indicating cytotoxic T-cell differentiation. The malignant T cells in both cases were of host tissue origin. Both cases were negative for Epstein-Barr virus genome using Southern blot analysis. The patients did not respond to reduction of immunosuppression. Despite initial response to chemotherapy, both patients died within 6 months of diagnosis. Our findings indicate that gamma-delta HSTCL can occur as a late complication in transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761449     DOI: 10.1309/YTTC-F55W-K9CP-EPX5

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

Review 1.  Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review.

Authors:  V Costes-Martineau; C Delfour; S Obled; L Lamant; G-P Pageaux; P Baldet; P Blanc; G Delsol
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

2.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

3.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

4.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.

Authors:  Martin H Voss; Matthew A Lunning; Jocelyn C Maragulia; Esperanza B Papadopoulos; Jenna Goldberg; Andrew D Zelenetz; Steven M Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-27

Review 5.  Pathobiology of T-cell and NK-cell lymphomas.

Authors:  Ewa B Bajor-Dattilo; Stefania Pittaluga; Elaine S Jaffe
Journal:  Best Pract Res Clin Haematol       Date:  2013-05-23       Impact factor: 3.020

Review 6.  Hematologic abnormalities following renal transplantation.

Authors:  Mark A Marinella
Journal:  Int Urol Nephrol       Date:  2009-03-20       Impact factor: 2.266

Review 7.  Biology and management of rare primary extranodal T-cell lymphomas.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Oncology (Williston Park)       Date:  2010-01       Impact factor: 2.533

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.